7 1	
AD	

Award Number: DAMD17-00-1-0566

TITLE: Vitronectin and Integrin $\alpha v \beta 3$ in Ovarian Carcinoma

PRINCIPAL INVESTIGATOR: Shuang Huang, Ph.D.

CONTRACTING ORGANIZATION: The Scripps Research Institute

La Jolla, California 92037

REPORT DATE: July 2001

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command

Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;

Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Papervork Reduction Project (0704-0188), Washington, DC 20503

Management and Budget, Paperwork Reduction Proje	ect (0704-0188), Washington, DC 20503	, <u> </u>				
1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE	3. REPORT TYPE ANI				
	July 2001	Annual (1 Jul				
4. TITLE AND SUBTITLE Vitronectin and Integrin ανβ3 in Ovarian Carcinoma			5. FUNDING NUMBERS DAMD17-00-1-0566			
6. AUTHOR(S)			1			
Shuang Huang, Ph.D.						
7. PERFORMING ORGANIZATION NAM	ME(S) AND ADDRESS(ES)		8. PERFORMING ORGANIZATION REPORT NUMBER			
The Scripps Research						
La Jolla, California	92037					
E-Mail: shuang@scripps.edu						
9. SPONSORING / MONITORING AGE	NCY NAME(S) AND ADDRESS	(ES)		NG / MONITORING REPORT NUMBER		
U.S. Army Medical Research and M	Materiel Command		AGENCII	EFORT HOWIDER		
Fort Detrick, Maryland 21702-5012						
, ,						
44 CURRITARY NOTES			<u></u>			
11. SUPPLEMENTARY NOTES						
A DISTRIBUTION / AVAILABILITY	OTA TERRET			12b. DISTRIBUTION CODE		
12a. DISTRIBUTION / AVAILABILITY S Approved for Public Rele		nlimited		12B. DISTRIBUTION CODE		
inpproved for rustro more	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,					
13. Abstract (Maximum 200 Words) (One hallmark of ovarian canc	<u>abstract should contain no prop</u>	o <u>rietary or confidential info</u>	<i>rmation)</i> a cells in asci	tes However it is		
unknown how ovarian cancer						
cancer cells express vitronect			•			
for ovarian cancer cell surviv						
induced NF-κB activation; Su						
of NF-κB family showed that	-	•		=		
NF-kB activity in ovarian car	_					
· · · · · · · · · · · · · · · · · · ·			-			
negative form of IkB or using						
κB activity resulted in over 8						
significantly affect the surviv						
vitronectin/ανβ3 interaction-				il survival in absence of		
adhesion, and may explain w	hy ovarian cancer cells c	an survive in susper	ision.			
				AT AUGUSTO OF TAXABLE		
14. SUBJECT TERMS			1	15. NUMBER OF PAGES		

Unclassified NSN 7540-01-280-5500

OF REPORT

17. SECURITY CLASSIFICATION

αv integrin. vitronectin. cell survival

18. SECURITY CLASSIFICATION

Unclassified

OF THIS PAGE

Standard Form 298 (Rev. 2-89) Prescribed by ANSI Std. 239-18 298-102

20. LIMITATION OF ABSTRACT

Unlimited

16. PRICE CODE

19. SECURITY CLASSIFICATION

Unclassified

OF ABSTRACT

Table of Contents

Cover	
SF 298	2
Table of Contents	3
Introduction	4
Body	4-5
Key Research Accomplishments	5
Reportable Outcomes	5
Conclusions	5
References	N/A
Appendices	N/A

INTRODUCTION:

The objective of this proposal is to investigate the importance of vitronectin (Vn) and $\alpha\nu\beta3$ integrin in ovarian cancer. The three main goals of this proposal is to 1) examine the mechanism of Vn/ $\alpha\nu\beta3$ -mediated ovarian cancer cell survival in suspension culture; 2) to develop potent hammerhead ribozymes targeted against Vn and the $\beta3$ integrin subunit; 3) to suppress the efficacy of adenovirus-delivered Vn and $\beta3$ integrin subunit-specific ribozymes to suppress tumorigenicity of human ovarian cancer cells in both *in vitro* and *in vivo* experimental models. We believe the better understanding the role of Vn and $\alpha\nu\beta3$ integrin in ovarian cancer cell invasion and survival may lead to a novel therapeutic strategy for ovary malignancies.

BODY:

We have accomplished all of first year goals (described as Task 1 in our approved Statement of Work).

In the first part of our study, we have measured the effect of engaging αv integrins with immobilized Vn on NF-кB activity in human ovarian cancer cells. Ovarian cancer OVCAR5 and OVCAR3 cells were transfected with an NF-κB-dependent promoter luciferase reporter gene plasmid, and then added on the culture dishes coated with Vn (2µg/ml) for 2 to 24 hrs. The significant increase in luciferase activity (8-11 fold over the control plasmid-transfected cells) was detected as early as 4 hrs and sustained in all 24 hr period. In a parallel experiment, we also performed electrophoresis mobility shift assay (EMSA). Nuclear extracts were isolated from OVCAR5 and OVCAR3 cells plated on Vn-coated surface for 4 hrs, and then incubated with an oligonucleotide containing NF-kB consensus sequence (Promega) for 30 min. By fractionating the reaction, we found that the mobility of NF-kB consensus sequence-containing oligonucleotide, rather than the mutant NF-kB oligonucleotide, was shifted, further confirming the ability of Vn/αv integrin ligation to induce NF-κB activity. Furthermore, we also performed super EMSA by incubating nucleus/oligonucleotide complex with antibodies to specific member of NF-kB factor. We found that NF-kB members, p65 and p50, were involved in $\alpha v\beta 3$ integrin-mediated NF- κB activity. To determine which αv integrin mediates induced NF-κB activity, we pretreated cells with function-blocking mAb to β1 integrin (P4C10), ανβ3 (LM609) or ανβ5 (P1F6) prior to adding cells on Vncoated surface. We found that Vn-induced NF- κB activity is mediated by $\alpha \nu \beta 3$ integrin rather than $\alpha v\beta 5$ or $\alpha v\beta 1$ integrin since only function-blocking monoclonal antibody to αvβ3 was capable of abrogating Vn-induced NF-κB activity.

In the second part of our study, we determined the importance of NF- κB activity in ovarian cancer cell survival in suspension culture. We prepared a recombinant adenoviral vector containing dominant negative $I\kappa B$ gene under tetracycline promoter

control (Ad.tet.IkBm) and tetracycline-inducible OVCAR5 cell line (OVCAR5-tet). OVCAR5-tet cells were infected with Ad.tet.IkBm (10pfu/cell) for 24 hrs, and then added in HEMA-coated culture dishes. These cells grew well on HEMA surface (in absence of adhesion); however, the addition of tetracycline, which induced the expression of dominant negative IkB, resulted in over 80% of cell death in a two-day culture period. In a parallel study, we also tested the sensitivity of ovarian cancer cells in suspension to NF-kB inhibitors, D609 (CalBiochem) and SN50 (BIOMOL). Treatment of OVCAR5 and OVCAR3 with D609 and SN50 induced 46.9 and 33.3% of cell death in first day and 81.2 and 77.2% of cell death in second day, respectively. The results from these studies strongly suggest that $Vn/\alpha v\beta 3$ ligation-induced NF-kB activity is essential for ovarian cancer cell survival in suspension.

KEY RESEARCH ACCOMPLISHMENTS:

- We found that extracellular matrix vitronectin induced NF- κB activity via $\alpha v \beta 3$ integrin in human ovarian cancer cells.
- We found that $\alpha \nu \beta 3$ integrin-mediated NF- κB activity is essential for ovarian cancer cell survival in suspension.

REPORTABLE OUTCOME:

1. Han, Q., New, L., Chen, J., Pan, Z.K., and Huang, S. (2001). Expression of urokinase-specific surface receptor on human carcinoma cells is regulated by interaction with urokinase plasminogen activator. Submitted for *J.Biol.Chem*.

CONCLUSIONS:

One hallmark of ovarian cancer is the presence of adhering cells on peritoneal surface and floating cells in the ascites. However, it is not clear how ovarian cancer cells can survive in absence of adhesion. Our early studies showed that ovarian cancer cells express both vitronectin and $\alpha\nu\beta3$ integrin on the cell surface, and the interaction between vitronectin and $\alpha\nu\beta3$ integrin is essential for ovarian cancer cell survial in suspension. In our recent study, we demonstrated that vitronectin and $\alpha\nu\beta3$ interaction induced NF-kB activation and this induced NF-kB activity is essential for ovarian cancer cell survival. Our present study may explain why ovarian cancer cells can survive in suspension and implicate a novel strategy for ovarian cancer by disrupting or inhibiting vitronectin/ $\alpha\nu\beta3$ integrin expression.

D	T.	F	r i	D.	r	N	1	T	C	

None

APPENDICES:

None